January 12, 2015 / 4:38 PM / 3 years ago

BUZZ-Tekmira Pharmaceuticals: Surges on deal to boost Hep B drugs portfolio

(Updates)

** Canadian biopharmaceutical company’s U.S.-listed stock up 45 pct at $22.81, on track for second-best day ever

** Canada-listed shares up 45 pct at C$27.26; still neither listing near their 52-week highs

** Tekmira to buy OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods

** U.S.- and Canadian listed stock among top percentage gainers; U.S. stock, with more than 8 mln shares traded, among most active on the Nasdaq

** Implied market value of the merged company is about $750 mln, Tekmira to continue with oncology and anti-viral programs, including Ebola

** “We think this is a very good deal for Tekmira’s shareholders as this could now be the leading pure-play and public Hepatitis B company,” says RBC analyst Michael Yee

** Through Friday, U.S.-listed shares have halved and Canada-listed stock had fallen 46 pct since their 52-week highs in March

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below